Form 8-K · Current Report · Filed 2025-11-24
Halozyme Therapeutics CFO Departure
Halozyme Therapeutics, Inc. announced that Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will leave the company by March 30, 2026. She will be eligible for certain benefits, including her 2025 annual bonus at 120% target-level individual performance, a cash payment equal to her annual base salary plus pro-rated 2026 bonus if separation occurs during 2026, vesting of outstanding equity awards, an extension of option exercise period, and healthcare coverage. The transition is part of a previously disclosed plan.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-25-000061
- CIK
- 0001159036
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Market reaction
Close before filing
$70.34
Next session
+3.5%
Since filing
+56.7%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.